Research programme: taxoid prodrug molecules - Biocon
Latest Information Update: 10 Apr 2007
At a glance
- Originator Biocon
- Class
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Apr 2004 This programme is still in active development
- 01 Apr 2003 No development reported - Preclinical for Cancer in USA (Injection)
- 01 Apr 2003 No development reported - Preclinical for Cancer in USA (PO)